



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/514,427	11/16/2004	Sui Xiong Cai	1735.0770001/RWE/CJW	4080
26111	7590	01/22/2008	EXAMINER	
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005				O'DELL, DAVID K
ART UNIT		PAPER NUMBER		
				1625
MAIL DATE		DELIVERY MODE		
01/22/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/514,427	CAI ET AL.	
	<b>Examiner</b> David K. O'Dell	<b>Art Unit</b> 1625	

All participants (applicant, applicant's representative, PTO personnel):

(1) David K. O'Dell. *DO*

(3) Rita Desai. *RD*

(2) Robert Esmond. *RE*

(4) Stephanie Elmer *SLE*

Date of Interview: 16 January 2008.

Type: a) Telephonic b) Video Conference  
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.

If Yes, brief description: Data on prior art compounds vs. instant.

Claim(s) discussed: All.

Identification of prior art discussed: U.S. 7,053,117

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

RITA DESAI  
PRIMARY EXAMINER  
*Rita Desai*  
1/16/08









Examiner's signature, if required





Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.





Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments:

Applicant's presented unexpected results for the methylated analogs that were rejected under 103(a). The scope of various substituents was discussed in terms of how to make and use.

**Exhibit A**

Compound	T-47D EC <sub>50</sub> (μM)	2R-75-1 EC <sub>50</sub> (μM) <sup>*1</sup>	Compound	T-47D EC <sub>50</sub> (μM)	2R-75-1 EC <sub>50</sub> (μM)
94* <sup>2</sup> 	.049	.025	27* <sup>3</sup> 	.014	.0071
97* <sup>2</sup> 	.006	.007	16* <sup>3</sup> 	.0016	.001
99* <sup>2</sup> 	.036	.023	24* <sup>3</sup> 	.0034	.0022
2F* <sup>4</sup> 	.044	.026	40D* <sup>3</sup> 	.025	.015
2G* <sup>4</sup> 	.056	.025	40C* <sup>3</sup> 	.014	.0079
2K* <sup>4</sup> 	.037	.016	30* <sup>3</sup> 	.0073	.0034

Compound	T-47D EC <sub>50</sub> (μM)	2R-75-1 EC <sub>50</sub> (μM)	Compound	T-47D EC <sub>50</sub> (μM)	2R-75-1 EC <sub>50</sub> (μM)
46* <sup>4</sup> 	.0618	.0263	28* <sup>3</sup> 	.0072	.0033
57* <sup>4</sup> 	.0580	.0279	1* <sup>3</sup> 	.0255	.0065
59* <sup>4</sup> 	>10	>10	3* <sup>3</sup> 	.0581	.0278
2L* <sup>4</sup> 	.063	.041	40A* <sup>3</sup> 	.014	.0072
50* <sup>4</sup> 	.0165	.0148	18* <sup>3</sup> 	.0060	.0034
36* <sup>5</sup> 	.010	.003	11* <sup>3</sup> 	.0029	.0011

Compound	T-47D EC <sub>50</sub> (μM)	2R-75-1 EC <sub>50</sub> (μM)	Compound	T-47D EC <sub>50</sub> (μM)	2R-75-1 EC <sub>50</sub> (μM)
35 <sup>*5</sup> 	.003	.008	10 <sup>*3</sup> 	.0023	.0016
41 <sup>*5</sup> 	.0139	.0066	41 <sup>*3</sup> 	.004	.002

<sup>\*1</sup> The units have been changed to μM from the nm used in the as-filed specification.

<sup>\*2</sup> U.S. Patent No. 6,906,203 B1 (U.S. Patent Appl. Pub. No. 2001/034591 A2)

<sup>\*3</sup> as-filed specification

<sup>\*4</sup> U.S. Patent No. 7,053,117 B2

<sup>\*5</sup> U.S. Patent Appl. Pub. No. 2006/0035925 A1